JP7078620B2 - アレルギーの治療のための核酸 - Google Patents

アレルギーの治療のための核酸 Download PDF

Info

Publication number
JP7078620B2
JP7078620B2 JP2019524956A JP2019524956A JP7078620B2 JP 7078620 B2 JP7078620 B2 JP 7078620B2 JP 2019524956 A JP2019524956 A JP 2019524956A JP 2019524956 A JP2019524956 A JP 2019524956A JP 7078620 B2 JP7078620 B2 JP 7078620B2
Authority
JP
Japan
Prior art keywords
seq
nucleic acid
allergen
cell
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019524956A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019537447A (ja
Inventor
テリー ハイラント,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomic Therapeutics Inc
Original Assignee
Immunomic Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomic Therapeutics Inc filed Critical Immunomic Therapeutics Inc
Publication of JP2019537447A publication Critical patent/JP2019537447A/ja
Priority to JP2022082014A priority Critical patent/JP2022119861A/ja
Application granted granted Critical
Publication of JP7078620B2 publication Critical patent/JP7078620B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019524956A 2016-11-16 2017-11-15 アレルギーの治療のための核酸 Active JP7078620B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022082014A JP2022119861A (ja) 2016-11-16 2022-05-19 アレルギーの治療のための核酸

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662423111P 2016-11-16 2016-11-16
US62/423,111 2016-11-16
US201762536088P 2017-07-24 2017-07-24
US62/536,088 2017-07-24
PCT/US2017/061847 WO2018093932A2 (en) 2016-11-16 2017-11-15 Nucleic acids for treatment of allergies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022082014A Division JP2022119861A (ja) 2016-11-16 2022-05-19 アレルギーの治療のための核酸

Publications (2)

Publication Number Publication Date
JP2019537447A JP2019537447A (ja) 2019-12-26
JP7078620B2 true JP7078620B2 (ja) 2022-05-31

Family

ID=60582661

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019524956A Active JP7078620B2 (ja) 2016-11-16 2017-11-15 アレルギーの治療のための核酸
JP2022082014A Pending JP2022119861A (ja) 2016-11-16 2022-05-19 アレルギーの治療のための核酸

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022082014A Pending JP2022119861A (ja) 2016-11-16 2022-05-19 アレルギーの治療のための核酸

Country Status (6)

Country Link
US (1) US11826423B2 (cg-RX-API-DMAC10.html)
EP (1) EP3541420A2 (cg-RX-API-DMAC10.html)
JP (2) JP7078620B2 (cg-RX-API-DMAC10.html)
CN (1) CN110418650A (cg-RX-API-DMAC10.html)
CA (1) CA3044074A1 (cg-RX-API-DMAC10.html)
WO (1) WO2018093932A2 (cg-RX-API-DMAC10.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2861240T3 (pl) * 2012-06-15 2021-07-05 Immunomic Therapeutics, Inc. Kwasy nukleinowe do leczenia alergii
US11452774B2 (en) 2015-02-20 2022-09-27 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10149904B2 (en) 2015-02-20 2018-12-11 The Board Of Trusteees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10166286B2 (en) 2015-02-20 2019-01-01 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
CN111465328A (zh) 2017-07-18 2020-07-28 前品牌股份有限公司 制备混合型变应原组合物的方法
WO2019216394A1 (ja) * 2018-05-11 2019-11-14 アステラス製薬株式会社 ダニアレルギー治療のための核酸
CA3099505A1 (en) * 2018-05-11 2019-11-14 Astellas Pharma Inc. Nucleic acid for treating crustacean allergy
JP2021523185A (ja) * 2018-05-15 2021-09-02 イミュノミック セラピューティックス, インコーポレイテッドImmunomic Therapeutics, Inc. アレルゲンを含む改善されたlamp構築物
EP3831401A4 (en) * 2018-06-22 2022-04-20 Zonhon Biopharma Institute, Inc. RECOMBINANT DUST MITE ALLERGEN PROTEIN MIXTURE AND USE THEREOF
US11766477B2 (en) 2019-01-23 2023-09-26 Societe Des Produits Nestle S.A. Methods for making mixed allergen compositions
CN111138514B (zh) * 2020-01-08 2023-09-22 海南大学 一种腰果多肽及其提取方法和应用
CN117003848A (zh) * 2022-11-10 2023-11-07 浙江鼎持生物制品有限公司 猫主要过敏原蛋白表达、纯化和组合应用
US20260216320A1 (en) * 2023-01-17 2026-07-30 Société des Produits Nestlé S.A. Mixed nut allergen formulations and methods of making and using the same
WO2025139524A1 (zh) * 2023-12-28 2025-07-03 江苏众红生物工程创药研究院有限公司 猫重组变应原及其药用组合物、制备方法和应用
WO2025247235A1 (en) * 2024-05-29 2025-12-04 Therorna Shanghai Co., Ltd. Methods of inducing tumor specific t cells with a circular rna cancer vaccine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015200357A2 (en) 2014-06-23 2015-12-30 Immunomic Therapeutics, Inc. Nucleic acids for treatment of peanut allergies

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237115A (en) 1977-11-23 1980-12-02 Bactex, Inc. Method of immunization against enterotoxogenic infection by Escherichia coli
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4397844A (en) 1978-02-24 1983-08-09 Ciba-Geigy Corporation Antigen derivatives and processes for their preparation
GB2026340B (en) 1978-07-03 1982-12-22 Ash P Stabilising microvesicles
US4681762A (en) 1979-05-23 1987-07-21 Research Corporation Genetically attenuated bacterial vaccines with multiple mutations of the same phenotype
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4593002A (en) 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4592002A (en) 1983-12-13 1986-05-27 Honeywell Inc. Method of digital temperature compensation and a digital data handling system utilizing the same
ZA858044B (en) 1984-11-01 1987-05-27 American Home Prod Oral vaccines
FR2583429B1 (fr) 1985-06-18 1989-11-03 Transgene Sa Vecteur d'expression de l'interferon u dans les cellules de mammifere, procede pour sa mise en oeuvre et produit obtenu et composition pharmaceutique contenant l'interferon u
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
DE3642912A1 (de) 1986-12-16 1988-06-30 Leybold Ag Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5744166A (en) 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
US5100587A (en) 1989-11-13 1992-03-31 The United States Of America As Represented By The Department Of Energy Solid-state radioluminescent zeolite-containing composition and light sources
US5179993A (en) 1991-03-26 1993-01-19 Hughes Aircraft Company Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid
HU220462B1 (hu) * 1991-10-16 2002-02-28 Immulogic Pharmaceutical Corp. A Dermatophagoides nemzetség allergénjéből származó peptidek, ezeket tartalmazó gyógyszerkészítmények és eljárás házi poratka-érzékenység kimutatására
SE503225C2 (sv) 1991-10-30 1996-04-22 Leif Lindholm Konsult Ab Virus-antikroppskomplex för införing av virus i mammalieceller
US5747323A (en) 1992-12-31 1998-05-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Retroviral vectors comprising a VL30-derived psi region
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2707091B1 (fr) 1993-06-30 1997-04-04 Cohen Haguenauer Odile Vecteur rétroviral pour le transfert et l'expression de gènes dans des cellules eucaryotes.
US5928944A (en) 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
MX9504664A (es) 1994-03-07 1997-05-31 Dow Chemical Co Conjugados de dendrimeros bioactivos y/o dirigidos.
JPH10501963A (ja) 1994-04-15 1998-02-24 ターゲテッド ジェネティクス コーポレイション 遺伝子送達融合タンパク質
FR2719316B1 (fr) 1994-04-28 1996-05-31 Idm Nouveaux complexes d'acide nucléique et de polymère, leur procédé de préparation et leur utilisation pour la transfection de cellules.
WO1996000295A1 (en) 1994-06-27 1996-01-04 The Johns Hopkins University Targeted gene delivery system
FR2722506B1 (fr) 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa Composition contenant des acides nucleiques, preparation et utilisations
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
FR2737222B1 (fr) 1995-07-24 1997-10-17 Transgene Sa Nouveaux vecteurs viraux et lignee pour la therapie genique
WO1997035996A1 (en) 1996-03-25 1997-10-02 Transgene S.A. Packaging cell line based on human 293 cells
JP2000514290A (ja) 1996-07-01 2000-10-31 ローヌ―プーラン・ロレ・エス・アー 組換えアデノウイルスの製造方法
AU3739697A (en) 1996-07-09 1998-02-02 Johns Hopkins University, The Gene delivery system
IL130198A (en) 1996-12-13 2005-09-25 Schering Corp Methods for purifying viruses
FR2759382A1 (fr) 1997-02-10 1998-08-14 Transgene Sa Nouveaux composes et compositions les contenant utilisables pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
FR2760193B1 (fr) 1997-02-28 1999-05-28 Transgene Sa Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules
FR2763958A1 (fr) 1997-05-29 1998-12-04 Transgene Sa Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique
JP2002506436A (ja) 1997-06-13 2002-02-26 ザ ジョンズ ホプキンス ユニバーシティー 治療用ナノスフェア
AU707186B2 (en) 1997-07-01 1999-07-01 Transgene S.A. Compositions useful for transferring therapeutically active substances into a target cell, and their use in gene therapy
ES2180258T3 (es) 1998-07-07 2003-02-01 Transgene Sa Utilizacion de pautas de lectura abierta adenovirales de e4 para mejorar la expresion de genes.
CA2364934C (fr) 1999-02-22 2011-10-18 Transgene S.A. Procede d'obtention d'une preparation virale purifiee
ES2404689T3 (es) 2001-04-05 2013-05-28 The Johns Hopkins University Vacunas quiméricas que comprenden el dominio lumenal de LAMP-1 o LAMP-2
AU2003256240A1 (en) 2002-08-29 2004-03-19 National University Of Singapore Recombinant nucleic acid useful for inducing protective immune response against allergens
WO2004109291A2 (en) 2003-06-02 2004-12-16 Mount Sinai School Of Medecine Of New York University Method for diagnosis and therapy of hazelnut-induced systemic reaction
EP2028188A1 (en) 2007-08-21 2009-02-25 Biomay AG Hypoallergenic molecules
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
PL2861240T3 (pl) * 2012-06-15 2021-07-05 Immunomic Therapeutics, Inc. Kwasy nukleinowe do leczenia alergii

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015200357A2 (en) 2014-06-23 2015-12-30 Immunomic Therapeutics, Inc. Nucleic acids for treatment of peanut allergies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J ALLERGY CLIN IMMUNOL,vol.131, no.5,p.1384-1392
Journal of Immunology Research,2016年04月30日,vol.2016, Article ID 4857869,p.1-15

Also Published As

Publication number Publication date
US11826423B2 (en) 2023-11-28
CN110418650A (zh) 2019-11-05
JP2019537447A (ja) 2019-12-26
EP3541420A2 (en) 2019-09-25
WO2018093932A2 (en) 2018-05-24
CA3044074A1 (en) 2018-05-24
WO2018093932A3 (en) 2018-06-28
US20190351050A1 (en) 2019-11-21
JP2022119861A (ja) 2022-08-17

Similar Documents

Publication Publication Date Title
US11826423B2 (en) Nucleic acids for treatment of allergies
US11110164B2 (en) Lysosomal targeting of antigens employing nucleic acids encoding lysosomal membrane polypeptide/antigen chimeras
US12116396B2 (en) LAMP constructs
JP3581366B2 (ja) 免疫原のリソソーム標的
AU2002307145A1 (en) Chimeric vaccines
EP2869828B1 (en) Vault immunotherapy
JP7742900B2 (ja) アレルゲンを含む改善されたlamp構築物
HK40123095A (en) Improved lamp constructs
HK40014081B (en) Improved lamp constructs
HK40014081A (en) Improved lamp constructs

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201021

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210902

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220302

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220421

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220519

R150 Certificate of patent or registration of utility model

Ref document number: 7078620

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250